Jeremy P. Bost

Jeremy P. Bost

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2020 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
DGDhanu Gupta
Dhanu Gupta
XLXiuming Liang
Xiuming Liang
SPSvetlana Pavlova
Svetlana Pavlova
OWOscar P.B. Wiklander
Oscar P.B. Wiklander
GCGiulia Corso
Giulia Corso
OGOskar Gustafsson
Oskar Gustafsson
Extracellular vesicles (EVs) are naturally occurring nano-sized carriers that are secreted by cells and facilitate cell-to-cell communication by their unique ability to transfer biologically active cargo. Despite the pronounced increase in our understanding of EVs over the last decade, from disease pathophysiology to therapeutic drug delivery, improved molecular tools to track their therapeutic delivery are still needed. Unfortunately, the present catalogue of tools utilised for EV labelling lacks sensitivity or are not sufficiently specific. Here, we have explored the bioluminescent labelling of EVs using different luciferase enzymes tethered to CD63 to achieve a highly sensitive system for in vitro and in vivo tracking of EVs. Using tetraspanin fusions to either NanoLuc or ThermoLuc permits performing highly sensitive in vivo quantification of EVs or real-time imaging, respectively, at low cost and in a semi-high throughput manner. We find that the in vivo distribution pattern of EVs is determined by the route of injection, but that different EV subpopulations display differences in biodistribution patterns. By applying this technology for real-time non-invasive in vivo imaging of EVs, we show that their distribution to different internal organs occurs just minutes after administration. Graphical abstract

10 September 2021 in ACS Nano
Verified
Journal Article
Open access
JBJeremy P. Bost
Jeremy P. Bost
HBHanna Barriga
Hanna Barriga
MHMargaret N. Holme
Margaret N. Holme
Audrey GalludAudrey Gallud
Audrey Gallud
MMMarco Maugeri
Marco Maugeri
OGOskar Gustafsson
Oskar Gustafsson
Oligonucleotides (ONs) comprise a rapidly growing class of therapeutics. In recent years, the list of FDA-approved ON therapies has rapidly expanded. ONs are small (15–30 bp) nucleotide-based therapeutics which are capable of targeting DNA and RNA as well as other biomolecules. ONs can be subdivided into several classes based on their chemical modifications and on the mechanisms of their target interactions. Historically, the largest hindrance to the widespread usage of ON therapeutics has been their inability to effectively internalize into cells and escape from endosomes to reach their molecular targets in the cytosol or nucleus. While cell uptake has been improved, “endosomal escape” remains a significant problem. There are a range of approaches to overcome this, and in this review, we focus on three: altering the chemical structure of the ONs, formulating synthetic, lipid-based nanoparticles to encapsulate the ONs, or biologically loading the ONs into extracellular vesicles. This review provides a background to the design and mode of action of existing FDA-approved ONs. It presents the most common ON classifications and chemical modifications from a fundamental scientific perspective and provides a roadmap of the cellular uptake pathways by which ONs are trafficked. Finally, this review delves into each of the above-mentioned approaches to ON delivery, highlighting the scientific principles behind each and covering recent advances.

29 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
XLXiuming Liang
Xiuming Liang
DGDhanu Gupta
Dhanu Gupta
JXJunhua Xie
Junhua Xie
EWElien Van Wonterghem
Elien Van Wonterghem
LHLien Van Hoecke
Lien Van Hoecke
OGOskar Gustafsson
Oskar Gustafsson
Intracellular delivery of protein and RNA therapeutics represents a major challenge. Here, we develop highly potent engineered extracellular vesicles (EVs) by incorporating bio-inspired attributes required for effective delivery. These comprise an engineered mini-intein protein with self-cleavage activity for active cargo loading and release, and fusogenic VSV-G protein for endosomal escape. Combining these components allows high efficiency recombination and genome editing in vitro following EV-mediated delivery of Cre recombinase and Cas9/sgRNA RNP cargoes, respectively. In vivo, infusion of a single dose Cre loaded EVs into the lateral ventricle in brain of Cre-LoxP R26-LSL-tdTomato reporter mice results in greater than 40% and 30% recombined cells in hippocampus and cortex respectively. In addition, we demonstrate therapeutic potential of this platform by showing inhibition of LPS-induced systemic inflammation via delivery of a super-repressor of NF-ĸB activity. Our data establish these engineered EVs as a platform for effective delivery of multimodal therapeutic cargoes, including for efficient genome editing.

1 September 2023 in Science Advances
Verified
Journal Article
Open access
DHDaniel Hagey
Daniel Hagey
MOMiina Ojansivu
Miina Ojansivu
BBBeklem R. Bostancioglu
Beklem R. Bostancioglu
Osama SaherOsama Saher
Osama Saher
JBJeremy P. Bost
Jeremy P. Bost
SASamir EL Andaloussi
Samir EL Andaloussi
Extracellular vesicles (EVs) have been established to play important roles in cell-cell communication and shown promise as therapeutic agents. However, we still lack a basic understanding of how cells respond upon exposure to EVs from different cell sources at various doses. Thus, we treated fibroblasts with EVs from 12 different cell sources at doses between 20 and 200,000 per cell, analyzed their transcriptional effects, and functionally confirmed the findings in various cell types in vitro, and in vivo using single-cell RNA sequencing. Unbiased global analysis revealed EV dose to have a more significant effect than cell source, such that high doses down-regulated exocytosis and up-regulated lysosomal activity. However, EV cell source–specific responses were observed at low doses, and these reflected the activities of the EV’s source cells. Last, we assessed EV-derived transcript abundance and found that immune cell-derived EVs were most associated with recipient cells. Together, this study provides important insights into the cellular response to EVs.

7 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
WZWenyi Zheng
Wenyi Zheng
JRJulia Rädler
Julia Rädler
HSHelena Sork
Helena Sork
ZNZheyu Niu
Zheyu Niu
SRSamantha Roudi
Samantha Roudi
OGOskar Gustafsson
Oskar Gustafsson
Extracellular vesicles (EVs) are gaining ground as next-generation drug delivery modalities. Genetic fusion of the protein of interest to a scaffold protein with high EV-sorting ability represents a robust cargo loading strategy. To address the paucity of such scaffold proteins, we leverage a simple and reliable assay that can distinguish intravesicular cargo proteins from surface- as well as non-vesicular proteins and compare the EV-sorting potential of 244 candidate proteins. We identify 24 proteins with conserved EV-sorting abilities across five types of producer cells. TSPAN2 and TSPAN3 emerge as lead candidates and outperform the well-studied CD63 scaffold. Importantly, these engineered EVs show promise as delivery vehicles in cell cultures and mice as demonstrated by efficient transfer of luminal cargo proteins as well as surface display of different functional entities. The discovery of these scaffolds provides a platform for EV-based engineering.

21 November 2021 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
JBJeremy P. Bost
Jeremy P. Bost
Osama SaherOsama Saher
Osama Saher
DHDaniel Hagey
Daniel Hagey
DMDoste R. Mamand
Doste R. Mamand
XLXiuming Liang
Xiuming Liang
DGDhanu Gupta
Dhanu Gupta
Extracellular vesicles (EVs) are nanosized cell‐derived vesicles produced by all cells, which provide a route of intercellular communication by transmitting biological cargo. While EVs offer promise as therapeutic agents, the molecular mechanisms of EV biogenesis are not yet fully elucidated, in part due to the concurrence of numerous interwoven pathways which give rise to heterogenous EV populations in vitro. The equilibrium between the EV‐producing pathways is heavily influenced by factors in the extracellular environment, in such a way that can be taken advantage of to boost production of engineered EVs. In this study, a quantifiable EV‐engineering approach is used to investigate how different cell media conditions alter EV production. The presence of serum, exogenous EVs, and other signaling factors in cell media alters EV production at the physical, molecular, and transcriptional levels. Further, it is demonstrated that the ceramide‐dependent EV biogenesis route is the major pathway to production of engineered EVs during optimized EV‐production. These findings suggest a novel understanding to the mechanisms underlying EV production in cell culture which can be applied to develop advanced EV production methods.